1.1 The case for adopting HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography (CCTA) is supported by the evidence. The technology is non-invasive and safe, and has a high level of diagnostic accuracy.
1.2 HeartFlow FFRCT should be considered as an option for patients with stable, recent-onset chest pain who are offered CCTA in line with the NICE guideline on chest pain. Using HeartFlow FFRCT may avoid the need for invasive coronary angiography and revascularisation. For correct use, HeartFlow FFRCT requires access to 64‑slice (or above) CCTA facilities.
1.3 Based on the current evidence and assuming there is access to appropriate CCTA facilities, using HeartFlow FFRCT may lead to cost savings of £391 per patient . By adopting this technology, the NHS in England may save a minimum of £9.4 million by 2022 through avoiding invasive investigation and treatment .